Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pudafensine in Vulvodynia
NCT07391241Phase 2Recruiting
- Sponsor
- Initiator Pharma A/S
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pudafensine in vulvodynia, sponsored by Initiator Pharma A/S. Primary endpoint: Effect of pudafensine on pain in the vaginal vestibule (vestibular pain threshold) using the Vestibular Pain Threshold Test at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
pudafensine
03
Conditions
vulvodynia
Beyond the preview
Go deeper on NCT07391241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391241.